个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Time to abandon CAR-T monotherapy for solid tumors

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yin Limei[1,2] * ; Wan Zhengwei[1,2] ; Sun Ping[1,2] ; Shuai Ping[1,2,*1] ; Liu Yuping[1,2,*1] ;
机构： [1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China [2]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China
出处：
DOI： 10.1016/j.bbcan.2023.188930
ISSN：

关键词： CAR-T Solid tumor Immunotherapy Combined therapy

摘要：
In recent decades, chimeric antigen receptor T (CAR-T) cell therapy has achieved dramatic success in patients with hematological malignancies. However, CAR-T cell therapy failed to effectively treat solid tumors as a monotherapy. By summarizing the challenges of CAR-T cell monotherapy for solid tumors and analyzing the underlying mechanisms of combinatorial strategies to counteract these hurdles, we found that complementary therapeutics are needed to improve the scant and transient responses of CAR-T cell monotherapy in solid tumors. Further data, especially data from multicenter clinical trials regarding efficacy, toxicity, and predictive biomarkers are required before the CAR-T combination therapy can be translated into clinical settings.Copyright © 2023. Published by Elsevier B.V.

基金：
"Tianfu Million-People Program"/Tianfu Famous Physician Program, Chengdu, China (No. TF013), the key research and development project of Sichuan Science and Technology Department (2022YFS0600) and the Medical and Engineer Cross Joint Fund of University of Electronic Science and Technology of China (ZYGX2021YGLH208).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 2 区 生化与分子生物学 2 区 生物物理 2 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 生化与分子生物学 2 区 生物物理 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 BIOPHYSICS Q1 ONCOLOGY
最新[2023]版：
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 BIOPHYSICS Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China [2]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China
通讯作者：
通讯机构： [1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China [2]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China [*1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China.
推荐引用方式(GB/T 7714)：
Yin Limei,Wan Zhengwei,Sun Ping,et al.Time to abandon CAR-T monotherapy for solid tumors[J].BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER.2023,1878(4):doi:10.1016/j.bbcan.2023.188930.
APA：
Yin Limei,Wan Zhengwei,Sun Ping,Shuai Ping&Liu Yuping.(2023).Time to abandon CAR-T monotherapy for solid tumors.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,1878,(4)
MLA：
Yin Limei,et al."Time to abandon CAR-T monotherapy for solid tumors".BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1878..4(2023)

相关文献

[1]Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress [2]New Approaches in CAR-T Cell Immunotherapy for Breast Cancer [3]Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy [4]Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies. [5]Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022) [6]Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy [7]Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial [8]A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy [9]CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer [10]Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号